Skip to main content

Sanofi Value Stock - Dividend - Research Selection

Sanofi S.A.

ISIN: FR0000120578, WKN: 920657

Market price date: 21.05.2021
Market price: 88,47 EUR

Sanofi S.A. Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 14-03-2021
Cash flow
Net operating cash flow 7.449.000.000
Capital Expenditures -
Free cash flow 5.335.000.064
Balance sheet
Total Equity
Liabilities & Shareholders equity 114.529.000.000
Income statement
Net income 12.314.000.000
Eps (diluted) 9,770
Diluted shares outstanding 1.250.690.000
Net sales/revenue 37.369.000.000

Fundamental ratios calculated on: 21-05-2021

Key figures 21-05-2021
Cash flow
P/C 14,85
P/FC 20,74
Balance sheet
Income statement
Div. Yield3,62%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization134.200.778.752,00 USD
IndicesCAC 40,EURO STOXX 50
Raw Data SourceIFRS in Millionen EUR
Stock Split

Description of the company

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Company's principal activities. Under the Company's Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,